Current Status and Research Progress of Immunotheray for Limited Stage Small Cell Lung Cancer
Limited stage small cell lung cancer(SCLC)has strong invasiveness and poor progno-sis.Except for a few patients in the very early stage who have the opportunity for surgery,concur-rent chemoradiotherapy remains the standard treatment for non-surgical limited stage SCLC.The e-merging immunotherapy has brought opportunities for SCLC,meanwhile,the combination of chemoradiotherapy with immunotherapy has both benefits and shortcomings,making it a research hotpot in SCLC treatment.This paper reviews the current status and research progress of immune checkpoint inhibitor(ICI)therapy,including the timing of immunotherapy intervention(immunother-apy following concurrent/sequential chemoradiotherapy,immunotherapy in combination with con-current/sequential chemoradiotherapy),the combination of different ICIs(PD-L1/PD-1 inhibitors,CTLA-4 inhibitors,anti-BTLA,TIGIT antibodies,DLL3 antibodies),and the doses of radiothera-py and fractionation patterns with immunotherapy.The current progress in this field indicates that the potential of immunotherapy during standard radiotherapy and chemotherapy is worth further exploring.
small cell lung cancerlimited stageimmunotherapyradiotherapyclinical trials
NETL
NSTL
万方数据
